{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:30:02Z","timestamp":1787689802897,"version":"build-2784847793"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Individuals with mood and psychotic disorders are at an increased risk for dementia. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of antidiabetic medications with mitochondrial and metabolic properties, may offer protective benefits.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether treatment with SGLT2 inhibitors is associated with reduced risk of incident dementia and other neuropsychiatric outcomes in patients with psychiatric disorders.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used a target trial emulation design and data from the US Department of Veterans Affairs databases from January 1, 2016, to June 1, 2024. Participants were 65 years or older with a diagnosis of major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder but without prior dementia diagnosis at baseline or history of SGLT2 inhibitor use. Analyses used marginal structural models weighted by inverse probability of treatment and censoring.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Initiation and noninitiation of SGLT2 inhibitor were calculated using intention-to-treat (ITT) analysis, and sustained and nonsustained use of SGLT2 inhibitor for \u22653 months were estimated using per-protocol (PP) analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was incident all-cause dementia, as defined by\n International Classification of Diseases<\/jats:italic>\n \u2013coded diagnoses. Secondary outcomes were time to psychiatric emergency department (PED) visit and time to psychiatric hospitalizations. Covariates included demographic characteristics, comorbidities, psychiatric diagnoses, and medication use.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, there were 112\u202f725 individuals in the sample, of whom 7631 (6.8%) were exposed to an SGLT2 inhibitor. The sample had a median (IQR) age of 74.1 (69.7-77.6) years and predominantly consisted of males (104\u202f818 [92.8%]); 49.3% of the patients had obesity. In the ITT analysis, SGLT2 inhibitor use was associated with reduced odds of all-cause dementia (odds ratio [OR], 0.61; 95% CI, 0.52-0.73) and PED visits (OR, 0.80; 95% CI, 0.66-0.97) but not psychiatric hospitalizations (OR, 0.68; 95% CI, 0.44-1.04). In the PP analysis, SGLT2 inhibitor use was associated with lower odds of all-cause dementia (OR, 0.54; 95% CI, 0.40-0.73) and psychiatric hospitalizations (OR, 0.56; 95% CI, 0.31-1.00) but not PED visits (OR, 0.74; 95% CI, 0.53-1.05).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of older adults with mood and psychotic disorders, SGLT2 inhibitor use was associated with lower risk of dementia and PED visits. The results support a neuroprotective role of SGLT2 inhibitors in a high-risk psychiatric population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.19985","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:00:15Z","timestamp":1782846015000},"page":"e2619985","source":"Crossref","is-referenced-by-count":1,"title":["Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders"],"prefix":"10.1001","volume":"9","author":[{"given":"David T.","family":"Liebers","sequence":"first","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshe","family":"He","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Betensky","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, NYU School of Global Public Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin N.","family":"Swinnerton","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linden","family":"Huhmann","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan V.","family":"Do","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gilsanz","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo S.","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Pomara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Convit","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan V.","family":"Iosifescu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Ramos-Cejudo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University (NYU) Grossman School of Medicine, New York"},{"name":"Veterans Affairs (VA) Boston Cooperative Studies Program, Massachusetts Veterans Epidemiology Research and Information Collaborative, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Neurology, NYU Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"6","key":"zoi260555r1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamapsychiatry.2021.0042","article-title":"Age-specific prevalence and incidence of dementia diagnoses among older US adults with schizophrenia.","volume":"78","author":"Stroup","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"zoi260555r2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1176\/appi.ps.201900325","article-title":"Increased risk of dementia among veterans with bipolar disorder or schizophrenia receiving care in the VA health system.","volume":"71","author":"Ahearn","year":"2020","journal-title":"Psychiatr Serv"},{"issue":"9","key":"zoi260555r3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamaneurol.2023.2309","article-title":"Association of early-, middle-, and late-life depression with incident dementia in a Danish Cohort.","volume":"80","author":"Elser","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"zoi260555r4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4088\/JCP.v66n0205","article-title":"Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.","volume":"66","author":"Goff","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"zoi260555r5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11920-023-01457-1","article-title":"Magnetic resonance spectroscopy studies of brain energy metabolism in schizophrenia: progression from prodrome to chronic psychosis.","volume":"25","author":"Stein","year":"2023","journal-title":"Curr Psychiatry Rep"},{"key":"zoi260555r6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ibneur.2023.04.002","article-title":"Mitochondria dysfunction and bipolar disorder: from pathology to therapy.","volume":"14","author":"Lam","year":"2023","journal-title":"IBRO Neurosci Rep"},{"issue":"1","key":"zoi260555r7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-023-00364-y","article-title":"Brain metabolism in Alzheimer\u2019s disease: biological mechanisms of exercise.","volume":"12","author":"Xu","year":"2023","journal-title":"Transl Neurodegener"},{"key":"zoi260555r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2019.01.016","article-title":"Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression.","volume":"315","author":"Hamer","year":"2019","journal-title":"Exp Neurol"},{"issue":"5","key":"zoi260555r9","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41380-022-01494-x","article-title":"Schizophrenia: a disorder of broken brain bioenergetics.","volume":"27","author":"Henkel","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"11","key":"zoi260555r10","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.239","article-title":"Elevated brain lactate in schizophrenia: a 7?T magnetic resonance spectroscopy study.","volume":"6","author":"Rowland","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"3","key":"zoi260555r11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2478\/jtim-2022-0024","article-title":"Aberrant energy metabolism in Alzheimer\u2019s disease.","volume":"10","author":"Yu","year":"2022","journal-title":"J Transl Int Med"},{"key":"zoi260555r12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.636174","article-title":"Insulin resistance and blood-brain barrier dysfunction underlie neuroprogression in bipolar disorder.","volume":"12","author":"Calkin","year":"2021","journal-title":"Front Psychiatry"},{"issue":"2","key":"zoi260555r13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14022","article-title":"Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): a randomized, quadruple-masked, placebo-controlled clinical trial.","volume":"83","author":"Calkin","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"zoi260555r14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.114.152850","article-title":"Insulin resistance and outcome in bipolar disorder.","volume":"206","author":"Calkin","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"6","key":"zoi260555r15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/advances\/nmaa073","article-title":"To keto or not to keto? A systematic review of randomized controlled trials assessing the effects of ketogenic therapy on Alzheimer disease.","volume":"11","author":"Grammatikopoulou","year":"2020","journal-title":"Adv Nutr"},{"key":"zoi260555r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115866","article-title":"Ketogenic diet intervention on metabolic and psychiatric health in bipolar and schizophrenia: a pilot trial.","volume":"335","author":"Sethi","year":"2024","journal-title":"Psychiatry Res"},{"issue":"16","key":"zoi260555r17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260555r18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMe2500233","article-title":"Another win for SGLT2 inhibitors in chronic kidney disease.","volume":"392","author":"Leaf","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260555r19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"issue":"5","key":"zoi260555r20","article-title":"The role of ketogenic metabolic therapy on the brain in serious mental illness: a review.","volume":"7","author":"Sethi","year":"2022","journal-title":"J Psychiatr Brain Sci"},{"issue":"21","key":"zoi260555r21","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.3390\/cells11213372","article-title":"Empagliflozin induced ketosis, upregulated IGF-1\/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics.","volume":"11","author":"Avgerinos","year":"2022","journal-title":"Cells"},{"issue":"5","key":"zoi260555r22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41386-022-01364-8","article-title":"Acute administration of ketone beta-hydroxybutyrate downregulates 7T proton magnetic resonance spectroscopy-derived levels of anterior and posterior cingulate GABA and glutamate in healthy adults.","volume":"48","author":"Hone-Blanchet","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"zoi260555r23","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.841","article-title":"A pilot study of a ketogenic diet in bipolar disorder: clinical, metabolic and magnetic resonance spectroscopy findings.","volume":"11","author":"Campbell","year":"2025","journal-title":"BJPsych Open"},{"issue":"23","key":"zoi260555r24","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors.","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"zoi260555r25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/biof.1998","article-title":"Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice.","volume":"50","author":"Gui","year":"2024","journal-title":"Biofactors"},{"issue":"19","key":"zoi260555r26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cells11193107","article-title":"Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia.","volume":"11","author":"Heimke","year":"2022","journal-title":"Cells"},{"issue":"12","key":"zoi260555r27","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1080\/00207454.2024.2414270","article-title":"Empagliflozin ameliorates olfactory bulbectomy-induced depression by mitigating oxidative stress and possible involvement of brain derived neurotrophic factor in diabetic rats.","volume":"135","author":"Borikar","year":"2025","journal-title":"Int J Neurosci"},{"key":"zoi260555r28","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00313","article-title":"The interplay between MiR-134\/BDNF and LKB1\/AMPK\/SIRT1 accentuates the antidepressant efficacy of empagliflozin in ovariectomized rats.","author":"Fathy","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"zoi260555r29","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00213-024-06663-0","article-title":"Empagliflozin-activated AMPK elicits neuroprotective properties in reserpine-induced depression via regulating dynamics of hippocampal autophagy\/inflammation and PKC?-mediated neurogenesis.","volume":"241","author":"Muhammad","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"zoi260555r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2022.105715","article-title":"Diabetes, antidiabetic medications and risk of depression - a population-based cohort and nested case-control study.","volume":"140","author":"Wium-Andersen","year":"2022","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"zoi260555r31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study.","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"zoi260555r32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00592-023-02063-6","article-title":"Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.","volume":"60","author":"Mui","year":"2023","journal-title":"Acta Diabetol"},{"key":"zoi260555r33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis.","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"zoi260555r34","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.536","article-title":"Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: a retrospective cohort study.","volume":"7","author":"Akimoto","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"zoi260555r35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study.","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"6","key":"zoi260555r36","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70313","article-title":"Heterogeneous treatment effects of GLP-1RAs and SGLT2is on risk of Alzheimer\u2019s disease and related dementia in patients with type 2 diabetes: insights from a real-world target trial emulation.","volume":"21","author":"Tang","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi260555r37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"12","key":"zoi260555r38","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent Reporting of Observational Studies Emulating a Target Trial-The TARGET Statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"zoi260555r39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/NAQ.0000000000000118","article-title":"The Veterans Affairs\u2019s Corporate Data Warehouse: uses and implications for nursing research and practice.","volume":"39","author":"Price","year":"2015","journal-title":"Nurs Adm Q"},{"issue":"6","key":"zoi260555r40","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1002\/alz.13853","article-title":"Antidepressant exposure and long-term dementia risk in a nationwide retrospective study on US veterans with midlife major depressive disorder.","volume":"20","author":"Ramos-Cejudo","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"6","key":"zoi260555r41","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/alz.12870","article-title":"Alzheimer\u2019s disease and related dementias among aging veterans: examining gene-by-environment interactions with post-traumatic stress disorder and traumatic brain injury.","volume":"19","author":"Logue","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260555r42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10742-018-0178-3","article-title":"Using Veterans Affairs Corporate Data Warehouse to identify 30-day hospital readmissions.","volume":"18","author":"Vincent","year":"2018","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"zoi260555r44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies.","volume":"96","author":"Danaei","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"zoi260555r45","doi-asserted-by":"publisher","first-page":"e1322","DOI":"10.1212\/WNL.0000000000010433","article-title":"Emulating a target trial of statin use and risk of dementia using cohort data.","volume":"95","author":"Caniglia","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"zoi260555r46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213855","article-title":"Statin initiation and dementia incidence in a large health care system from 1997 to 2020: a target trial emulation study.","volume":"105","author":"Zimmerman","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"zoi260555r47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data.","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi260555r48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes.","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"zoi260555r49","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1007\/s00210-024-03660-0","article-title":"Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan.","volume":"398","author":"Chuang","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"zoi260555r50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.amjmed.2024.06.030","article-title":"Association between SGLT2 inhibitors and risk of dementia and Parkinson\u2019s disease: a meta-analysis of 12 randomized controlled trials.","volume":"137","author":"Jaiswal","year":"2024","journal-title":"Am J Med"},{"key":"zoi260555r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116592","article-title":"Efficacy and safety of GLP1-RAs compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: a Danish nationwide target-trial emulation study.","volume":"351","author":"Jacobsen","year":"2025","journal-title":"Psychiatry Res"},{"key":"zoi260555r52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1601118","article-title":"Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study.","volume":"16","author":"Chang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"zoi260555r53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2174\/1570159X19666210517114016","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease: opportunities for drug development.","volume":"20","author":"Bhatia","year":"2022","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"zoi260555r54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/HRP.0000000000000374","article-title":"Sodium-glucose cotransporter-2 inhibitors in depression.","volume":"31","author":"Liebers","year":"2023","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"zoi260555r55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11064-018-2588-6","article-title":"A ketogenic diet improves mitochondrial biogenesis and bioenergetics via the PGC1a-SIRT3-UCP2 axis.","volume":"44","author":"Hasan-Olive","year":"2019","journal-title":"Neurochem Res"},{"issue":"11","key":"zoi260555r56","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1073\/pnas.1913042117","article-title":"Diet modulates brain network stability, a biomarker for brain aging, in young adults.","volume":"117","author":"Mujica-Parodi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi260555r57","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.951376","article-title":"The ketogenic diet for refractory mental illness: a retrospective analysis of 31 inpatients.","volume":"13","author":"Danan","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi260555r58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12888-024-05627-0","article-title":"Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.","volume":"24","author":"Zandifar","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"2","key":"zoi260555r59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.","volume":"21","author":"Dave","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"zoi260555r43","unstructured":"Su? L, Rezvani? R, Seaman? SR, Starr? C, Gravestock? I. TrialEmulation: an R package to emulate target trials for causal analysis of observational time-to-event data.? arXiv. Preprint posted online February 19, 2024. doi:10.48550\/arXiv.2402.12083"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850964\/liebers_2026_oi_260555_1782829157.38412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:00:21Z","timestamp":1782846021000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.19985","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}